Piper Jaffray maintains an Overweight rating on Salix Pharmaceuticals (Nasdaq: SLXP), raises price target from $17 to $29.

Piper analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE